SCYNEXIS To Present Preclinical Data On Second Generation Fungerp SCY-247 At The 11th Advances Against Aspergillosis And Mucormycosis Conference, January 25 – 27, in Milan, Italy
Portfolio Pulse from Benzinga Newsdesk
SCYNEXIS, Inc. announced the presentation of preclinical efficacy data on its antifungal candidate SCY-247 at the AAAM Conference. The study, funded by the NIH, showed SCY-247's in vivo efficacy and significant survival improvement when combined with liposomal amphotericin B. SCY-247 is a novel glucan synthase inhibitor with potential oral and IV formulations, and SCYNEXIS plans to begin clinical studies by year end. The company hopes for FDA QIDP and Fast Track designations for SCY-247.
January 05, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SCYNEXIS's presentation of positive preclinical data for SCY-247 could positively influence investor sentiment, as the company moves towards clinical trials and seeks FDA designations.
The positive preclinical data for SCY-247 suggests potential for successful clinical trials and FDA designations, which are key catalysts for biotech stocks. The news could lead to increased investor interest and a potential short-term uptick in SCYX's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100